Abstract
It is not known what combination of bevacizumab and chemotherapy agents is the best therapeutic regimen. Comparative study results among the efficacies of bevacizumab plus chemotherapy remain controversial in patients with HER2-negative metastatic breast cancer. We searched Pubmed, Embase, and Cochrane Library Central Resister of Controlled Trials through were July 2019 for randomized controlled trials that evaluated the efficacy of bevacizumab plus chemotherapy in HER2-negative metastatic breast cancer. Data on included study characteristics, outcomes, and risk of bias were abstracted by two reviewers. A total of 16 RCT studies involving 5689 patients were included. The results showed that bevacizumab (Bev) - taxanes (Tax) - capecitabine (Cap) has highest-ranking and is probably more effective for prolonging progression-free survival (PFS) than Tax, Cap, Bev-Tax and Bev-Cap, which was no convincing differences among Bev-Cap-vinorelbine, Bev-Tax-everolimus, Bev-Tax-trebananib, Bev-exemestane, Bev-Cap-cyclophosphamide in Bev-containing regimens. For overall response rate (ORR), Bev-Tax-Cap is superior to Tax, Cap and Bev-Cap, while Bev-Tax-trebananib is superior to Cap. The cumulative probability ranking showed that Bev-Tax-Cap ...Continue Reading
References
Nov 18, 1971·The New England Journal of Medicine·J Folkman
Jan 1, 1995·Human Pathology·L F BrownS J Schnitt
Apr 9, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Michel Marty, Xavier Pivot
Jul 4, 2008·Nature Reviews. Cancer·Lee M Ellis, Daniel J Hicklin
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert GrayRobert L Comis
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David W MilesGilles Romieu
Mar 25, 2011·The Lancet Oncology·Miguel MartinUNKNOWN TRIO 010 investigators
Oct 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adam M BrufskyHope S Rugo
Jan 27, 2012·The New England Journal of Medicine·Gunter von MinckwitzUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups
Jan 27, 2012·The New England Journal of Medicine·Harry D BearNorman Wolmark
Jan 15, 2013·The Lancet Oncology·Istvan LangUNKNOWN Central European Cooperative Oncology Group
Oct 3, 2014·The Lancet Oncology·Joseph GligorovGiorgio Mustacchi
Dec 3, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S W LamUNKNOWN Dutch Breast Cancer Research Group
Dec 19, 2014·Breast Cancer Research and Treatment·Hans-Joachim LückSibylle Loibl
Mar 10, 2015·The Breast : Official Journal of the European Society of Mastology·Véronique DiérasDennis J Slamon
Oct 13, 2015·Breast Cancer Research and Treatment·Denise A YardleyJohn D Hainsworth
Feb 27, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O TrédanT Bachelot
Mar 2, 2016·Breast Cancer Research and Treatment·A WeltS Hegewisch-Becker
Aug 10, 2016·The Lancet Oncology·Christoph ZielinskiUNKNOWN TURANDOT investigators
Oct 12, 2016·BMC Cancer·Christoph RochlitzUNKNOWN Swiss Group for Clinical Cancer Research (SAKK)
Nov 8, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·David MilesJoyce O'Shaughnessy
Feb 6, 2017·Japanese Journal of Clinical Oncology·Norikazu MasudaMasahiro Kashiwaba
Aug 26, 2019·Aging·Yunhai LiGuosheng Ren